Patients with psoriasis, particularly those with risk factors and severe disease, should receive appropriate screening and preventative intervention.

Compared with foam vehicle, calcipotriol plus betamethasone dipropionate foam offers more rapid and effective itch relief, with associated significant improvements in sleep and Dermatology Life Quality Index scores.

Baricitinib, a Janus kinase inhibitor, is currently approved under the brand name Olumiant for the treatment of moderately-to-severely active rheumatoid arthritis.

Overall therapeutic response was statistically higher for patients in the combination therapy group vs either single agent group.

Investigators observed differences and similarities in molecular and histopathologic profiles in skin lesions of patients with psoriasis treated with risankizumab vs ustekinumab.

Jeuveau, an aesthetic-only neurotoxin, was evaluated in 2 US Phase 3 placebo-controlled trials and a European and Canadian Phase 3 head-to-head trial vs onabotulinumtoxinA (Botox Cosmetic; Allergan).

194 participants with mild to moderate atopic dermatitis were randomly assigned to receive vehicle cream or 0.1%, 0.3%, or 1.0% PAC‐14028 cream twice daily.

The investigators sought to determine how the natural environment or diet protects potentially at-risk populations from such allergic conditions as atopic dermatitis.

The ACIP and CDC have approved and released 2019 recommendations for the adult immunization schedule in the US.

Researchers sought to determine whether thermography can reliably and effectively distinguish between allergic and irritant contact dermatitis.